|
1) |
Cooperberg MR, Broering JM, Litwin MS, et al. The contemporary management of prostate cancer in the United States:lessons from the cancer of the prostate strategic urologic research endeavor(CapSURE), a national disease registry. J Urol. 2004;171(4):1393-401. |
2) |
Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan:2000 report from the Japanese Urological Association. Int J Urol. 2005;12(1):46-61. |
3) |
Carter CA, Donahue T, Sun L, et al. Temporarily deferred therapy(watchful waiting)for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol. 2003;21(21):4001-8. |
4) |
Zietman AL, Thakral H, Wilson L, et al. Conservative management of prostate cancer in the prostate specific antigen era:the incidence and time course of subsequent therapy. J Urol. 2001;166(5):1702-6. |
5) |
Choo R, Klotz L, Danjoux C, et al. Feasibility study:watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol. 2002;167(4):1664-9. |
6) |
Bacon CG, Giovannucci E, Testa M, et al. The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. J Urol. 2001;166(5):1804-10. |
7) |
George N. Therapeutic dilemmas in prostate cancer:justification for watchful waiting. Eur Urol. 1998;34 Suppl 3:33-6. |
8) |
Kakehi Y. Watchful waiting as a treatment option for localized prostate cancer in the PSA era. Jpn J Clin Oncol. 2003;33(1):1-5. |